Psoriatic Arthritis

The Pharmacy Times® Psoriatic Arthritis resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
Ron Lanton III, Esq, President, True North Political Solutions, makes predictions about how dealings with biosimilars may change in 2018.
[[thumbnail_alt_text]]
Tofacitinib (Xeljanz/Xeljanz XR) improves disease severity for patients with psoriatic arthritis.
[[thumbnail_alt_text]]
Up to 90% of patients with psoriasis develop plaque on their nails, palms of the hands, and soles of the feet.
[[thumbnail_alt_text]]
Hay fever and asthma are dependent on allergens that stimulate the immunoglobulin E pathway, which is not the case with atopic dermatitis.
[[thumbnail_alt_text]]
Ixekizumab found to provide significant improvement in joint symptoms for patients not previously treated with a biologic disease-modifying antirheumatic drug.
[[thumbnail_alt_text]]
Patients with moderate-to-severe nail psoriasis treated with secukinumab experienced significant improvement in the Nail Psoriasis Severity Index.
[[thumbnail_alt_text]]
Secukinumab (Cosentyx) treatment observed to improve the signs and symptoms of psoriatic arthritis.
[[thumbnail_alt_text]]
New Drug Applications filed for halobetasol propionate and tazarotene lotion, a topical treatment for plaque psoriasis.
[[thumbnail_alt_text]]
Treatment for psoriatic arthritis may impact symptoms and patient-reported outcomes.
[[thumbnail_alt_text]]
Patients with active psoriatic arthritis experience significant work instability based on disease activity.
[[thumbnail_alt_text]]
Several modalities found to be effective in the triage of psoriasis patients with musculoskeletal symptoms, according to a study presented at the 2017 American College of Rheumatology meeting.
[[thumbnail_alt_text]]
Risankizumab treats moderate to severe chronic plaque psoriasis.